Trial Profile
A study assessing omalizumab for the treatment of chronic spontaneous urticaria in clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2016 New trial record
- 06 Oct 2016 Results published in the Annals of Allergy, Asthma and Immunology